Skip to main content
. 2015 Jul 28;5:10648. doi: 10.1038/srep10648

Figure 4.

Figure 4

Kaplan–Meier estimates of (A) progression-free survival (PFS) and (B) overall survival (OS) in NSCLC in patients who received 500 mg/d (H group) or 250 mg/d (S group) gefitinib after achieving stable disease after one month of 250 mg/d gefitinib, stratified by EGFR mutations status.